May 19, 2020, Vol 323, No. 19, Pages 1873-1982
Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics
Andre C. Kalil, MD, MPH
free access has active quiz has audio
JAMA. 2020;323(19):1897-1898. doi:10.1001/jama.2020.4742
This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform their clinical use.
Clinical Review Audio: Coronavirus (COVID-19) Update: Chloroquine/Hydroxychloroquine and Azithromycin
Audio Interview: Coronavirus in New York – Report From the Front Lines